NDLI: Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs.

Please wait, while we are loading the content...

Year: 2017 Volume: 24

Year: 2016 Volume: 23

Year: 2015 Volume: 22

Year: 2014 Volume: 21

Year: 2013 Volume: 20

Year: 2012 Volume: 19

Year: 2012 Volume: 19 Issue: 6

Year: 2012 Volume: 19 Issue: 5

Year: 2012 Volume: 19 Issue: 4

Handling categories properly: a novel objective of clinical research.

Hydralazine-induced pulmonary-renal syndrome: a case report.

Disseminated tuberculosis secondary to adalimumab.

Diffuse alveolar damage and recurrent respiratory failure secondary to sertraline.

Statin therapy significantly reduces risk of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

Utilization of a reminder mailing to improve blood glucose log reporting in an outpatient diabetes clinic.

Adipocytes and cardiometabolic risk.

Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome.

A simple dose regimen of artesunate and amodiaquine based on age or body weight range for uncomplicated falciparum malaria in children: comparison of therapeutic efficacy with standard dose regimen of artesunate and amodiaquine and artemether-lumefantrine.

Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs.

Reduction of resting heart rate with antianginal drugs: review and meta-analysis.

Application of botulinum toxin to clinical therapy: advances and cautions.

An analysis of implantable cardiac device reliability. The case for improved postmarketing risk assessment and surveillance.

The human microbiome and therapeutics.

Recurrent lower extremity pseudocellulitis.

Year: 2012 Volume: 19 Issue: 3

Year: 2012 Volume: 19 Issue: 2

Year: 2012 Volume: 19 Issue: 1

Year: 2011 Volume: 18

Year: 2010 Volume: 17

Year: 2009 Volume: 16

Year: 2008 Volume: 15

Pulmonary arterial hypertension: classification and therapy with a focus on prostaglandin analogs.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Papierniak, Eric S. Lowenthal, David T. Mubarak, Kamal
Description	Country affiliation: United States Author Affiliation: Papierniak ES ( Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Florida, Gainesville, FL 32610, USA. papiee@medicine.ufl.edu)
Abstract	Pulmonary arterial hypertension, part of the larger spectrum of disorders causing pulmonary hypertension, is a complex and progressive disease of multiple etiologies that ultimately leads to vascular remodeling, right-sided heart failure, and death. Advances in treatment over the past 15 to 20 years have dramatically reduced the morbidity and mortality of the disease, but often have significant drawbacks. Of the more recently approved therapies, the prostaglandin analogs have been shown to have the greatest therapeutic benefit but are also the most difficult to administer, many being given as continuous intravenous infusions in the ambulatory setting. After a case presentation highlighting some of the challenges that accompany treatment with these agents, this article reviews the diagnosis and classification of pulmonary hypertension and pulmonary arterial hypertension and gives a brief overview of the various other pharmacologic agents used in its treatment. A more comprehensive review of the biochemistry of prostaglandins and the pharmacology and clinical use of this class of drugs follows. Recommended treatment guidelines are also discussed.
File Format	HTM / HTML
ISSN	10752765
Issue Number	4
Volume Number	19
e-ISSN	15363686
Journal	American Journal of Therapeutics
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2012-07-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Antihypertensive Agents Therapeutic Use Epoprostenol Analogs & Derivatives Hypertension, Pulmonary Drug Therapy Ambulatory Care Administration & Dosage Pharmacology Familial Primary Pulmonary Hypertension Female Humans Classification Physiopathology Infusions, Intravenous Middle Aged Practice Guidelines As Topic Prostaglandins Case Reports Journal Article Review
Content Type	Text
Resource Type	Case study Article
Subject	Pharmacology Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in